# Filing Detail

Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001104659-26-004337
Filing Date
2026-01-16
Accepted
2026-01-16 08:36:51
Documents
25

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 424B4 | tm2528002-19_424b4.htm | 424B4 | 2871041
2 | GRAPHIC | lg_metavia-4c.jpg | GRAPHIC | 11134
3 | GRAPHIC | fc_pipeline-4c.jpg | GRAPHIC | 61143
4 | GRAPHIC | fc_mash-4c.jpg | GRAPHIC | 19807
5 | GRAPHIC | bc_exploratoryp1b-4c.jpg | GRAPHIC | 18916
6 | GRAPHIC | bc_biomarker-4c.jpg | GRAPHIC | 19900
7 | GRAPHIC | bc_changesbaseline-4c.jpg | GRAPHIC | 37241
8 | GRAPHIC | bc_lsm1-4c.jpg | GRAPHIC | 42912
9 | GRAPHIC | bc_lsm2-4c.jpg | GRAPHIC | 43927
10 | GRAPHIC | bc_lsm3-4c.jpg | GRAPHIC | 32680
11 | GRAPHIC | bc_lsm4-4c.jpg | GRAPHIC | 53704
12 | GRAPHIC | bc_week16-4c.jpg | GRAPHIC | 50993
13 | GRAPHIC | bc_cfbpercentage-4c.jpg | GRAPHIC | 63627
14 | GRAPHIC | ph_oxyntomodulin-4c.jpg | GRAPHIC | 32924
15 | GRAPHIC | lc_preclinical-4clr.jpg | GRAPHIC | 39519
16 | GRAPHIC | bc_comparision-4clr.jpg | GRAPHIC | 49180
17 | GRAPHIC | tb_disposition-4c.jpg | GRAPHIC | 57821
18 | GRAPHIC | tb_baseline-4c.jpg | GRAPHIC | 50728
19 | GRAPHIC | tb_primarysafety-4c.jpg | GRAPHIC | 73657
20 | GRAPHIC | bc_exploratory-4c.jpg | GRAPHIC | 18138
21 | GRAPHIC | bc_exploratoryweight-4c.jpg | GRAPHIC | 29125
22 | GRAPHIC | tb_exploratorywaist-4c.jpg | GRAPHIC | 48822
23 | GRAPHIC | tb_fastedglucose-4c.jpg | GRAPHIC | 27552
24 | GRAPHIC | tb_vctechange-4c.jpg | GRAPHIC | 7360
25 | GRAPHIC | tb_pkphase1-4c.jpg | GRAPHIC | 134710
| Complete submission text file | 0001104659-26-004337.txt |  | 4282602

Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
MetaVia Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-292581 | Film No.: 26537724
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)